Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

BACKGROUND: The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) by 38.3 months after treatment with irinotecan, fluorouracil, and leucovorin (FOLFIRI)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Control
Glavni autori: Han, Jiaqi, Xiao, Desheng, Tan, Chongqing, Zeng, Xiaohui, Hu, Huabin, Zeng, Shan, Jiang, Qin, She, Longjiang, Yao, Linli, Li, Li, Tang, Lanhua, Ma, Jian, Huang, Jin, Shen, Liangfang
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053788/
https://ncbi.nlm.nih.gov/pubmed/32107929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1073274820902271
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items